Diatherix Laboratories

The companies will use their respective technologies to develop multiplex molecular diagnostic panels for laboratory testing.

Under the terms of the deal, IQuity's autoimmune disease diagnostics will be made available through Diatherix's CLIA-certified clinical laboratory.

The provider of multiplex diagnostics services and solutions will work with VUMC to develop infectious disease assays with a particular focus on pediatric patients.

Diatherix and Color Genomics now carry both CLIA certification and CAP accreditation.

The acquisition expands the firm's specialty clinical diagnostics footprint.

Enrichment prior to amplification better enables studies of non-coding regions and epigenetic analyses, according to Ubiquity's founder.

The contract is to further the company's work to develop methodologies aimed at Francisella tularensis, Escherichia coli, and Babesia microti.

Diatherix Laboratories, an independent CLIA-certified clinical laboratory providing multiplex molecular diagnostic services, said this week that it recently acquired from Qiagen the patent to target-enriched multiplexing, or TEM, PCR — a patent that Diatherix previously licensed

NEW YORK (GenomeWeb News) – Diatherix Laboratories today announced it has acquired from Qiagen a patent covering technology for rapidly identifying multiple infectious disease organisms.

The grants, awarded through the Qualifying Therapeutic Discovery Project Program created by the Patient Protection and Affordable Care Act of 2010, were disclosed last week by the IRS.

Pages

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.